Advertisement

Prodrugs pp 83-123 | Cite as

Topical Delivery Using Prodrugs

  • Kenneth B. Sloan
  • Scott C. Wasdo
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)

Abstract

The objective of any prodrug approach is to transiently mask a particular functional group in a drug and thus change its physicochemical properties (solubility profile, degree of ionization), protect it from premature chemical or biological metabolism, or facilitate its active or passive transport across a biological barrier, to name only a few of the more obvious applications. In the example of the use of a prodrug approach to enhance topical delivery, a change in the physicochemical properties of the drug is the objective. That change is designed to facilitate the passive absorption across the stratum corneum (SC)—wherein lies the major barrier to permeation—into the viable epidermis and beyond, if necessary. More complete descriptions of the skin can be found in other references (Barry, 1983). Here, we use the term “topical delivery” to include dermal delivery (delivery into the skin) and transdermal delivery (delivery through the skin into systemic circulation).

Keywords

Parent Drug Aqueous Solubility Receptor Phase Topical Delivery Hairless Mouse Skin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahmed S, Imai T, and Otagiri M. Evaluation of Stereoselective Transdermal Transport and Concurrent Cutaneous Hydrolysis of Several Ester Prodrugs of Propranolol: Mechanism of Stereoselective Permeation. Pharm Res 1996; 13:1524–1529PubMedCrossRefGoogle Scholar
  2. Barry B. Dermatological Formulations: Percutaneous Absorption. New York, NY: Marcel Dekker; 1983. 480 pGoogle Scholar
  3. Beall HD, and Sloan KB. Transdermal Delivery of 5-Fluorouracil (5-FU) by 1-Alkylcarbonyl-5-FU Prodrugs. Int J Pharm 1996; 129:203–210CrossRefGoogle Scholar
  4. Beall HD, and Sloan KB. Topical Delivery of 5-Fluorouracil (5-FU) by 3-Alkylcarbonyl-5-FU Prodrugs. Int J Pharm 2001; 217:127–137PubMedCrossRefGoogle Scholar
  5. Beall HD, and Sloan KB. Topical Delivery of 5-Fluorouracil (5-FU) by 1,3-Bisalkylcarbonyl-5-FU Prodrugs. Int J Pharm 2002; 231:43–49PubMedCrossRefGoogle Scholar
  6. Beall HD, Prankerd RJ, Todaro LJ, and Sloan KB. Structure of 3-Acetyl-5-fluorouracil (5-FU): Implication for Its Rearrangements During Hydrolysis and upon Heating. Pharm Res 1993; 10:905–912PubMedCrossRefGoogle Scholar
  7. Beall HD, Prankerd RJ, and Sloan KB. Transdermal Delivery of 5-Fluorouracil (5-FU) through Hairless Mouse Skin by 1-Alkyloxycarbonyl-5-FU Prodrugs: Physicochemical Characterization of Prodrugs and Correlations with Transdermal Delivery. Int J Pharm 1994; 111:223–233CrossRefGoogle Scholar
  8. Bodor N, and Sloan KB. Treating Psoriasis with Transient Prodrug Forms of Xanthine Derivatives. U.S. Patent 4,061,753, December 6, 1977. Chem Abstr 1977; 87:152278Google Scholar
  9. Bonina FP, Montenegro L, De Caprariis P, Bousquet E, and Tirendi S. 1-Alkylazacycloalkan-2-one Esters as Prodrugs of Indomethacin for Improved Delivery through Human Skin. Int J Pharm 1991; 77:21–29CrossRefGoogle Scholar
  10. Bonina FP, Montenegro L, and Guerrera F. Naproxen 1-Alkylazacycloalkan-2-one Esters as Dermal Prodrugs: In Vitro Evaluation. Int J Pharm 1993; 100:99–105CrossRefGoogle Scholar
  11. Bonina FP, Montenegro L, De Caprariis P, Palagiano F, Trapani G, and Liso G. In Vitro and In Vivo Evaluation of Polyoxyethylene Indomethacin Esters As Dermal Prodrugs. J Control Release 1995; 34:223–232CrossRefGoogle Scholar
  12. Bonina FP, Puglia C, Barbuzzi T, De Caprariis P, Palagiano F, Rimoli MG, and Saija A. In Vitro and In Vivo Evaluation of Polyoxyethylene Esters as Dermal Prodrugs of Ketoprofen, Naproxen and Diclofenac. Eur J Pharm Sci 2001; 14:123–134PubMedCrossRefGoogle Scholar
  13. Buur A, and Bundgaard H. Prodrug of 5-Fluorouracil V. 1-Alkoxycarbonyl Derivatives as Potential Prodrug Forms for Improved Rectal or Oral Delivery of 5-Fluorouracil. J Pharm Sci 1986; 75:522–527PubMedCrossRefGoogle Scholar
  14. Dillaha CJ, Jansen GT, Honeycutt MW, and Holt GA. Further Studies with 5-Flourouracil. Arch Dermatol 1965; 92:410–417PubMedCrossRefGoogle Scholar
  15. Drustrup J, Fullerton A, Christrup LL, and Bundgaard H. Utilization of Prodrugs to Enhance the Transdermal Absorption of Morphine. Int J Pharm 1991; 71:105–116CrossRefGoogle Scholar
  16. Friend, D, Catz P, Heller J, Reid J, and Baker R. Transdermal Delivery of Levonorgestrel II: Effect of Prodrug Structure on Skin Permeability In Vitro. J Control Release 1988; 7:251–261CrossRefGoogle Scholar
  17. Hadgraft J, and Pugh WJ. The Selection and Design of Topical and Transdermal Agents: A Review. J Invest Dermatol (Symposium Proceedings) 1998; 3:131–135Google Scholar
  18. Hansen LB, Fullerton A, Christrup LL, and Bundgaard H. Enhanced Transdermal Delivery of Ketobemidone with Prodrugs. Int J Pharm 1992; 84:253–260CrossRefGoogle Scholar
  19. Hou SYE, Mitra AK, White SH, Menon GK, Ghadially K, and Elias PM. Membrane Structures in Normal and Essential Fatty Acid-Deficient Stratum Corneum: Characterization by Ruthenium Tetroxide Staining and X-Ray Diffraction. J Invest Dermatol 1991; 96:215–223PubMedCrossRefGoogle Scholar
  20. Johansen M, and Bundgaard H. Pro-drugs as Drug Delivery Systems XII. Solubility, Dissolution and Partitioning Behavior of N-Mannich Bases and N-Hydroxymethyl Derivatives. Arch Pharm Chem Sci Edn 1980; 8:141–151Google Scholar
  21. Jona JA, Dittert LW, Crooks PA, Milosovich SM, and Hussain AA. Design of Novel Prodrugs for the Enhancement of the Transdermal Penetration of Indomethacin. Int J Pharm 1995; 123:127–136CrossRefGoogle Scholar
  22. Kawaguchi T, Fukushima S, Hayashi Y, and Nakano M. Nonenzymatic and Enzymatic Hydrolysis of 5-Fluoro-2’-deoxyuridine (FudR) Esters. Pharm Res 1988; 5:741–744PubMedCrossRefGoogle Scholar
  23. Kerr D, Roberts W, Tebbett I, and Sloan KB. 7-Alkylcarbonyloxymethyl Prodrugs of Theophylline: Topical Delivery of Theophylline. Int J Pharm 1998; 167:37–48CrossRefGoogle Scholar
  24. Koch SAM, and Sloan KB. N-Mannich Base Derivatives of 5-Fluorocytosine: A Prodrug Approach to Improve Topical Delivery. Int J Pharm 1987a; 35:243–252CrossRefGoogle Scholar
  25. Koch SAM, and Sloan KB. N-Mannich-Base Prodrugs of 5-Iodo-2’-deoxycytidine as Topical Delivery Enhancers. Pharm Res 1987b; 4:317–320PubMedCrossRefGoogle Scholar
  26. Lehtonen JYA, Holopainen JM, and Kinnunen PK. Evidence for the Formation of the Microdomains in Liquid Crystalline Large Unilamellar Vesicles Caused by Hydrophobic Mismatch of the Constituent Phospholipids. Biophys J 1996; 70:1753–1760PubMedCrossRefGoogle Scholar
  27. McKenzie AW, and Atkinson RM. Topical Activities of Betamethasone Esters in Man. Arch Dermatol 1964; 89:741–746PubMedCrossRefGoogle Scholar
  28. Milosovich S, Hussain A, Dittert L, Aungst B, and Hussain M. Testosteronyl-4-dimethylaminobutyrate HCl: A Prodrug with Improved Skin Penetration Rate. J Pharm Sci 1993; 82:227–228PubMedCrossRefGoogle Scholar
  29. Mollgaard B, Hoelgaard A, and Bundgaard H. Pro-drugs as Drug Delivery Systems XXIII. Improved Dermal Delivery of 5-Fluorouracil through Human Skin Via N-Acyloxymethyl Pro-Drug Derivatives. Int J Pharm 1982; 12:153–162CrossRefGoogle Scholar
  30. Ponec M, Kempencar J, Shroot B, and Caron J-C. Glucocorticoids: Binding Affinity and Lipophilicity. J Pharm Sci 1986; 75:973–975PubMedCrossRefGoogle Scholar
  31. Potts RO, and Guy RH. Predicting Skin Permeability. Pharm Res 1992; 9:663–669PubMedCrossRefGoogle Scholar
  32. Rautio J, Nevalainen T, Taipale H, Vepsalainen J, Gynther J, Pedersen T, and Jarvinen T. Synthesis and In Vitro Evaluation of Aminoacyloxyalkyl Esters of 2-(6-Methoxy-2-naphthyl) propionic Acid as Novel Naproxen Prodrugs for Dermal Drug Delivery. Pharm Res 1999; 16:1172–1178PubMedCrossRefGoogle Scholar
  33. Rautio J, Nevalainen T, Taipale H, Vepsalainen J, Gynther J, Laine K, and Jarvinen T. Synthesis and In Vitro Evaluation of Novel Morpholinyl-and Methylpiperazinylacyloxyalkyl Prodrugs of 2-(6-Methoxy-2-naphthyl) propionic Acid (Naproxen) for Topical Drug Delivery. J Med Chem 2000; 43:1489–1494PubMedCrossRefGoogle Scholar
  34. Roberts WJ, and Sloan KB. Correlation of Aqueous and Lipid Solubilities with Flux for Prodrugs of 5-Fluorouracil, Theophylline and 6-Mercaptopurine: A Potts-Guy Approach. J Pharm Sci 1999; 88:515–522PubMedCrossRefGoogle Scholar
  35. Roberts, WJ, and Sloan KB. Prediction of Transdermal Flux of Prodrugs of 5-Fluorouracil, Theophylline and 6-Mercaptopurine with a Series/Parallel Model. J Pharm Sci 2000; 89:1415–1431PubMedCrossRefGoogle Scholar
  36. Roberts WJ, and Sloan KB. Application of the Transformed Potts-Guy Equation to In Vivo Human Skin Data. J Pharm Sci 2001; 90:1318–1323PubMedCrossRefGoogle Scholar
  37. Roberts WJ, and Sloan KB. Topical Delivery of 5-Fluorouracil (5-FU) by 3-Alkylcarbonyloxymethyl-5-FU Prodrugs. J Pharm Sci 2003; 92:1028–1036PubMedCrossRefGoogle Scholar
  38. Sasaki H, Takahashi T, Mori Y, Nakamura J, and Shibasaki J. Transdermal Delivery of 5-Fluorouracil and its 1-Alkylcarbamoyl Derivatives. Int J Pharm 1990; 60:1–9CrossRefGoogle Scholar
  39. Scheuplein RJ, and Blank IH. Mechanism of Percutaneous Absorption IV. Penetration of Non-electrolytes (Alcohols) from Aqueous Solution and from Pure Liquids. J Invest Dermatol 1973; 60:286–296CrossRefGoogle Scholar
  40. Siver KG, and Sloan KB. The Effect of Structure of Mannich Base Prodrugs of 6-Mercaptopurine on their Ability to Deliver 6-Mercaptopurine through Hairless Mouse Skins. Int J Pharm 1988; 48:195–206CrossRefGoogle Scholar
  41. Siver KG, and Sloan KB. Alkylation of 6-Mercaptopurine (6-MP) with N-Alkyl-Nalkoxycarbonylaminomethyl Chlorides: S6-(N-Alkyl-N-alkoxycarbonyl) aminomethyl-6-MP Prodrug Structure Effect on the Dermal Delivery of 6-MP. J Pharm Sci 1990; 79:66–73PubMedCrossRefGoogle Scholar
  42. Sloan KB. Prodrugs for Dermal Delivery. Adv Drug Delivery Rev 1989; 3:67–101CrossRefGoogle Scholar
  43. Sloan KB. Functional Group Considerations in the Development of Prodrug Approaches to Solving Topical Delivery Problems. In: Sloan KB. Prodrugs: Topical and Ocular Drug Delivery, New York, NY: Marcel Dekker; 1992:17–116Google Scholar
  44. Sloan KB, and Bodor N. Hydroxymethyl and Acyloxymethyl Prodrugs of Theophylline: Enhanced Delivery of Polar Drugs through Skin. Int J Pharm 1982; 12:299–313CrossRefGoogle Scholar
  45. Sloan KB, and Wasdo SC. Designing for Topical Delivery: Prodrugs Can Make The Difference. Med Res Rev 2003; 23:763–793PubMedCrossRefGoogle Scholar
  46. Sloan KB, Koch SAM, and Siver KG. Mannich Base Derivatives of Theophylline and 5-Fluorouracil: Syntheses, Properties and Topical Delivery Characteristics. Int J Pharm 1984; 21:251–264CrossRefGoogle Scholar
  47. Sloan KB, Sherertz EF, and McTiernan RG. The Effect of Structure of Mannich Base Prodrugs on their Ability to Deliver Theophylline and 5-Fluorouracil through Hairless Mouse Skin. Int J Pharm 1988; 44:87–96CrossRefGoogle Scholar
  48. Sloan KB, Beall HD, Villanueva R, and Weimar WR. The Effect of Receptor Phase Composition on the Permeability of Hairless Mouse Skin in Diffusion Cell Experiments. Int. J Pharm. 1991; 73:97–104CrossRefGoogle Scholar
  49. Sloan KB, Getz JJ, Beall HD, and Prankerd RJ. Transdermal Delivery of 5-Fluorouracil (5-FU) through Hairless Mouse Skin by 1-Alkylaminocarbonyl-5-FU Prodrugs: Physiocochemical Characterization of Prodrugs and Correlations with Transdermal Delivery. Int J Pharm 1993; 93:27–36CrossRefGoogle Scholar
  50. Sloan KB, Taylor HE, and Hamilton JC. Alcohol Flux and Effect on the Delivery of Theophylline from Propylene Glycol. Int J Pharm 1997; 156:17–26CrossRefGoogle Scholar
  51. Sloan KB, Wasdo SC, Ezike-Mkparu U, Murray TJ, Nickels D. Singh S, Shank T, Tovar J, Ulmer K, and Waranis RP. Topical Delivery of 5-Fluorouracil and 6-Mercaptopurine by their Alkylcarbonyloxymethyl Prodrugs from Water: Vehicle Effects on Design of Prodrugs. Pharm Res 2003; 20:639–645PubMedCrossRefGoogle Scholar
  52. Stinchcomb AL, Paliwal A, Dua R, Imoto H, Woodard RW, and Flynn GL. Permeation of Buprenophine and Its 3-Alkyl-Ester Prodrugs through Human Skin. Pharm Res 1996; 13:1519–1523PubMedCrossRefGoogle Scholar
  53. Stinchcomb AL, Swaan PW, Ekabo O, Harris KK, Browe H, Hammell DC, Cooperman TA, and Pearsall M. Straight-Chain Naltrexone Ester Prodrugs: Diffusion and Concurrent Esterase Biotransformation in Human Skin. J Pharm Sci 2002; 91:2571–2578PubMedCrossRefGoogle Scholar
  54. Sung KC, Fang JY, and Hu OY. Delivery of Nalbuphine and its Prodrugs across Skin by Passive Diffusion and Iontophoresis. J Control Release 2000; 67:1–8PubMedCrossRefGoogle Scholar
  55. Taylor HE, and Sloan KB. 1-Alkylcarbonyloxymethyl Prodrugs of 5-Fluorouracil (5-FU): Synthesis, Physicochemical Properties and Topical Delivery of 5-FU. J Pharm Sci 1998; 87:15–20PubMedCrossRefGoogle Scholar
  56. Tsuji T, and Sugai T. Topical Administered Fluorouracil in Psoriasis. Arch Dermatol 1972; 105:208–212PubMedCrossRefGoogle Scholar
  57. van Hal DA, Jeremiasse E, Junginger HE, Spies F, and Bouwstra JA. Structure of Fully Hydrated Human Stratum Corneum: A Freeze-Fracture Electron Microscopy Study. J Invest Dermatol 1996; 106:89–95PubMedCrossRefGoogle Scholar
  58. Waranis RP, and Sloan KB, Effects of Vehicles and Prodrug Properties on the Delivery of 6-Mercaptopurine through Skin: Bisacyloxymethyl-6-mecaptopurine Prodrugs. J Pharm Sci 1987; 76:587–595PubMedCrossRefGoogle Scholar
  59. Waranis RP, and Sloan KB. Effects of Vehicles and Prodrug Properties on the Delivery of 6-Mercaptopurine through Skin: S6-Acyloxymethyl-6-mercaptopurine Prodrugs. J Pharm Sci 1988; 77:210–215PubMedCrossRefGoogle Scholar
  60. Wasdo SC, and Sloan KB. Topical Delivery of a Model Phenolic Drug: Alkyloxycarbonyl Prodrugs of Acetaminophen. Pharm Res 2004; 21:940–946PubMedCrossRefGoogle Scholar
  61. Wenkers BP, and Lippold BC. Skin Penetration of Nonsteroidal Antiiflammatory Drugs out of Lipophilic Vehicle: Influence of the Viable Epidermis. J Pharm Sci 1999; 88:1326–1331PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Kenneth B. Sloan
    • 1
  • Scott C. Wasdo
    • 1
  1. 1.Department of Medicinal ChemistryUniversity of FloridaGainesville

Personalised recommendations